Fig. 3From: Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trialForest plots showed independent influences on PFS in the TH group by multivariate analysis. Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; NLR, neutrophil to lymphocyte ratio; PFS, progression-free survival; TH group, trastuzumab plus docetaxel groupBack to article page